NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free ALT Stock Alerts $7.47 +0.56 (+8.10%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$6.85▼$7.5550-Day Range$6.89▼$13.8152-Week Range$2.09▼$14.84Volume2.34 million shsAverage Volume5.46 million shsMarket Capitalization$529.55 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Altimmune alerts: Email Address Altimmune MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside100.8% Upside$15.00 Price TargetShort InterestBearish25.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector659th out of 909 stocksPharmaceutical Preparations Industry297th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted25.01% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altimmune has recently increased by 41.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALT. Previous Next 3.2 News and Social Media Coverage News SentimentAltimmune has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Altimmune this week, compared to 4 articles on an average week.Search InterestOnly 78 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat Follows30 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 76% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($1.52) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Altimmune Stock (NASDAQ:ALT)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More ALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALT Stock News HeadlinesApril 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.April 22, 2024 | marketbeat.comWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (ALT)The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolioApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 9, 2024 | marketbeat.comCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon dual agonist similar to the weight-loss treatments Mounjaro and Zepbound by Eli Lilly and Co. NYSE: LLY.April 9, 2024 | marketbeat.comCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to marketMarch 28, 2024 | marketbeat.com7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.April 19, 2024 | finance.yahoo.comGlobal COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023April 18, 2024 | finance.yahoo.comAltimmune, Inc. (ALT)April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 12, 2024 | seekingalpha.comBuy Altimmune's Potential Market Disruption With PemvidutideApril 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024April 9, 2024 | fool.comForget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.April 1, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in April 2024April 1, 2024 | markets.businessinsider.comAltimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy RatingMarch 31, 2024 | seekingalpha.comEli Lilly: Three Threats To Its Huge RallyMarch 29, 2024 | msn.comA new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drugMarch 28, 2024 | finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | msn.comAltimmune says weight loss drug minimized muscle loss in trial results, which may set it apartMarch 28, 2024 | ca.finance.yahoo.comQ4 2023 Altimmune Inc Earnings CallMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass PreservationMarch 27, 2024 | seekingalpha.comAltimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In PlaceMarch 27, 2024 | cnbc.comAltimmune says weight loss drug minimized muscle loss in trial results that may set it apartMarch 27, 2024 | msn.comWhat To Know About Permvidutide—Altimmune Says Weight Loss Drug Minimized Muscle Mass Loss In TrialMarch 27, 2024 | investorplace.comALT Stock Earnings: Altimmune Beats EPS for Q4 2023March 27, 2024 | msn.comAltimmune GAAP EPS of -$0.54 misses by $0.16March 27, 2024 | finance.yahoo.comAltimmune Inc (ALT) Reports Q4 and Full Year 2023 Financial Results, Highlighting Pemvidutide's ...See More Headlines Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/22/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees59Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+100.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-20,780.75% Pretax Margin-20,762.21% Return on Equity-44.77% Return on Assets-40.72% Debt Debt-to-Equity RatioN/A Current Ratio17.26 Quick Ratio17.26 Sales & Book Value Annual Sales$430,000.00 Price / Sales1,231.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.72Miscellaneous Outstanding Shares70,890,000Free Float67,988,000Market Cap$529.55 million OptionableOptionable Beta0.05 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Vipin K. Garg Ph.D. (Age 66)President, CEO & Director Comp: $986.14kDr. Matthew Scott Harris AGAF (Age 71)FCAP, M.D., MS, Chief Medical Officer Comp: $681.81kMr. Raymond M. Jordt M.B.A. (Age 51)Chief Business Officer Comp: $578.85kMr. Richard I. Eisenstadt M.B.A. (Age 66)Chief Financial Officer Comp: $619.69kMr. Bertrand Georges Ph.D.Chief Technology OfficerDr. M. Scot Roberts Ph.D. (Age 65)Chief Scientific Officer Comp: $599.25kMr. Tony Blandin B.S.Vice President of Quality & Compliance ManagementMr. Andrew Shutterly M.S.Corporate ControllerMore ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCIGM BiosciencesNASDAQ:IGMSArbutus BiopharmaNASDAQ:ABUSCalliditas Therapeutics AB (publ)NASDAQ:CALTCOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsiders & InstitutionsIMC Chicago LLCBought 61,300 shares on 4/13/2024Ownership: 0.000%EWG Elevate Inc.Sold 5,000 shares on 4/10/2024Ownership: 0.014%Gerber LLCBought 255,778 shares on 3/5/2024Ownership: 0.476%Pennant Investors LPBought 109,800 shares on 2/14/2024Ownership: 0.204%Brown Wealth Management LLCBought 75,000 shares on 2/14/2024Ownership: 0.140%View All Insider TransactionsView All Institutional Transactions ALT Stock Analysis - Frequently Asked Questions Should I buy or sell Altimmune stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALT shares. View ALT analyst ratings or view top-rated stocks. What is Altimmune's stock price target for 2024? 3 equities research analysts have issued 1 year price targets for Altimmune's stock. Their ALT share price targets range from $12.00 to $20.00. On average, they anticipate the company's share price to reach $15.00 in the next year. This suggests a possible upside of 100.8% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts. How have ALT shares performed in 2024? Altimmune's stock was trading at $11.25 on January 1st, 2024. Since then, ALT shares have decreased by 33.6% and is now trading at $7.47. View the best growth stocks for 2024 here. When is Altimmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALT earnings forecast. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) issued its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.02. The company had revenue of $0.04 million for the quarter. Altimmune had a negative net margin of 20,780.75% and a negative trailing twelve-month return on equity of 44.77%. What ETF holds Altimmune's stock? Amplify Treatments, Testing and Advancements ETF holds 12,706 shares of ALT stock, representing 0.97% of its portfolio. When did Altimmune's stock split? Altimmune shares reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV). Who are Altimmune's major shareholders? Altimmune's stock is owned by a number of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%) and EWG Elevate Inc. (0.01%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
